Your browser doesn't support javascript.
loading
A genome-wide cell-free DNA methylation analysis identifies an episignature associated with metastatic luminal B breast cancer.
Rodriguez-Casanova, Aitor; Costa-Fraga, Nicolas; Castro-Carballeira, Clara; González-Conde, Miriam; Abuin, Carmen; Bao-Caamano, Aida; García-Caballero, Tomás; Brozos-Vazquez, Elena; Rodriguez-López, Carmela; Cebey, Victor; Palacios, Patricia; Cueva, Juan F; López-López, Rafael; Costa, Clotilde; Díaz-Lagares, Angel.
Afiliación
  • Rodriguez-Casanova A; Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
  • Costa-Fraga N; Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.
  • Castro-Carballeira C; Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
  • González-Conde M; Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
  • Abuin C; Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
  • Bao-Caamano A; Department of Oncology, Marqués de Valdecilla University Hospital, Santander, Spain.
  • García-Caballero T; Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.
  • Brozos-Vazquez E; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain.
  • Rodriguez-López C; Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain.
  • Cebey V; Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
  • Palacios P; Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.
  • Cueva JF; Department of Morphological Sciences, University of Santiago de Compostela and Xerencia de Xestión Integrada de Santiago (XXIS/SERGAS), Santiago de Compostela, Spain.
  • López-López R; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
  • Costa C; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
  • Díaz-Lagares A; Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
Front Cell Dev Biol ; 10: 1016955, 2022.
Article en En | MEDLINE | ID: mdl-36393855
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Cell Dev Biol Año: 2022 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Cell Dev Biol Año: 2022 Tipo del documento: Article País de afiliación: España